Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational Device ...

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

MARIA, a 42-year-old teacher with an energetic spirit, had always been an active woman. However, one morning after a long ...

Inquis Medical announced today that it completed enrollment in a pivotal trial evaluating its Aventus thrombectomy system.

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...

Blood clots are silent threats that can escalate quickly without warning. Recognizing their symptoms and taking immediate ...

AngioDynamics, Inc. (ANGO), a New York-based medical technology company Monday announced the publication of results from the Acute ...

Inquis Medical, which is developing therapies for venous thromboembolic diseases, announced the completion of patient ...

MANY clinical and experimental studies have been performed to study the etiology, diagnosis and treatment ... fat embolism," has been recognized. In documenting the first case of pulmonary and ...